Autonomix Medical, Inc. filed a Form 8-K on November 20, 2026, disclosing under Regulation FD that it posted an updated corporate presentation to its official website on that same date.

Key Highlights

  • Filing date: November 20, 2026, with November 20, 2026 as the date of earliest event reported.
  • Disclosure type: Item 7.01 Regulation FD Disclosure, covering an updated corporate presentation posted to the company's official website.
  • Exhibit: Exhibit 99.1 is described as an Investor Presentation dated November 2026.
  • Furnished, not filed: According to the filing, the information in Item 7.01, including Exhibit 99.1, "shall not be 'filed' for the purpose of the Securities Exchange Act of 1934."
  • Signatory: The report was signed by Trent Smith, Chief Financial Officer of Autonomix Medical, Inc.
  • Exchange listing: Common stock, par value $0.001 per share, is listed on NASDAQ:AMIX.

Autonomix Medical Furnishes Updated Corporate Presentation Under Regulation FD

Autonomix Medical, Inc., a Delaware-incorporated company headquartered at 21 Waterway Avenue, Suite 300, The Woodlands, TX 77380, filed a current report disclosing that on November 20, 2026, it posted an updated corporate presentation to its official website. The presentation is attached as Exhibit 99.1 and is described in the filing as an "Investor Presentation dated November 2026."

The filing was made under Item 7.01, Regulation FD Disclosure. The company stated in the filing that the information furnished under Item 7.01, including Exhibit 99.1, "is being furnished and shall not be 'filed' for the purpose of the Securities Exchange Act of 1934, as amended." The filing further noted that the information shall not be incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, "unless specifically identified therein as being incorporated by reference."

Autonomix Medical is an emerging growth company as indicated on the cover page of the filing. It has not elected to use the extended transition period for complying with new or revised financial accounting standards under Section 13(a) of the Exchange Act. The report was signed on behalf of the registrant by Trent Smith, Chief Financial Officer, on November 20, 2026.

What Was Disclosed

Autonomix Medical filed an 8-K on November 20, 2026 to disclose under Regulation FD the posting of an updated investor presentation to its website. The presentation is furnished as Exhibit 99.1 and is explicitly not deemed "filed" under securities law.